Drugs / Immune Globulin
Immune Globulin
also known as
IVIG · Cuvitru · human immunoglobulin · Ig20Gly · IGIV · IGSC · intravenous immunoglobulin
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial · 1 missed | ||||||
| Phase 0 | NCT00460928 | Apr 2007 → Jun 2009 | congenital heart block, neonatal lupus erythematosus | NYU Langone Health | Completed | Missed primary |
| Phase 11 trial | ||||||
| Phase 1 | NCT00195637 | Sep 2005 → Jul 2006 | hereditary inclusion-body myopathy | National Human Genome Research Institute (NHGRI) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05952804 | Jun 2024 → Jul 2028 expected | hematopoietic and lymphoid cell neoplasm | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07202078 | May 2025 → Mar 2027 expected | leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07202091 | May 2025 → Mar 2027 expected | leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT01218438 | Jan 2013 → Mar 2015 | immunodeficiency disease | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT04346108 | Aug 2020 → Dec 2021 | immunodeficiency disease | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 3 | NCT03166527 | Jun 2017 → Dec 2018 | polyneuropathy, inflammatory demyelinating, chronic | Vera Bril | Unknown | No outcome recorded |
| Phase 3 | NCT01992328 | Dec 2013 → Jan 2017 | asthma | Ajou University School of Medicine | Unknown | No outcome recorded |
| Phase 3 | NCT00004286 | Feb 1996 → Nov 1999 | chronic inflammatory demyelinating polyradiculoneuropathy | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 3 | NCT00004744 | Feb 1993 → Sep 1998 | multiple sclerosis | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 3 | NCT00004772 | Sep 1992 → ? | chronic inflammatory demyelinating polyradiculoneuropathy | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT00004407 | Feb 1998 → Mar 2000 | diabetic neuropathy | Mayo Clinic | Terminated | No outcome recorded |
| — | NCT00004833 | Jul 1995 → Nov 2002 | Guillain-Barre syndrome | Emory University | Terminated | No outcome recorded |
| — | NCT00004682 | Mar 1995 → Mar 1999 | myasthenia gravis | University of Texas | Terminated | No outcome recorded |
Press releases naming this drug 17 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | immune globulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00460928 ↗ |
| Known as | Cuvitru | “weekly 20% subcutaneous IG (SCIG; Cuvitru, Ig20Gly)” PMID 34036490 ↗ May 2021 |
| Known as | human immunoglobulin | “human immunoglobulin infusion (IVIg)” NCT00004833 ↗ |
| Known as | Ig20Gly | “weekly 20% subcutaneous IG (SCIG; Cuvitru, Ig20Gly)” PMID 34036490 ↗ May 2021 |
| Known as | IGIV | “Immune Globulin Intravenous (IGIV)” NCT04346108 ↗ |
| Known as | IGSC | “Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)” NCT04346108 ↗ |
| Known as | intravenous immunoglobulin | “Determine the effect of intravenous immunoglobulin on recovery time of patients with proximal diabetic neuropathy.” NCT00004407 ↗ |
| Known as | IVIG | “In this open-label pilot study, we propose to provide free sialic acid to muscle cells of HIBM patients by intravenous infusions of immune globulin (IvIg), a glycoprotein that...” NCT00195637 ↗5“treating the pregnant mother with intravenous immune globulin (IVIG) will prevent the development of CHB” NCT00460928 ↗ “intravenous human immune globulin (IVIG) or placebo” NCT00004286 ↗ “high-dose intravenous immune globulin (IVIG)” NCT00004744 ↗ “human immunoglobulin infusion (IVIg)” NCT00004833 ↗ “intravenous immune globulin (IVIG)” NCT00004772 ↗ |
| Action | Restore | “life-long intravenous (IV) or subcutaneous (SC) immunoglobulin (Ig) replacement therapy” PMID 27582171 ↗ Aug 2016 |
| Modality | Protein / enzyme biologic | “intravenous human immune globulin (IVIG)” NCT00004286 ↗ |
| Route | Intravenous | “intravenous human immune globulin (IVIG)” NCT00004286 ↗ |